Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids.2 As ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Systemic lupus erythematosus (SLE) is a systemic disease with cardiac manifestations, of which pericarditis is the most common (a lifetime risk of 25%) 1 and myocarditis a less common (5–10%)2 but ...

Introduction SLE is an autoimmune disease with an increased risk for poor outcomes in pregnancy. In 2020, ACR specified several recommendations to assist clinicians in preparing patients with SLE and ...

Objective Cognitive impairment (CI) is the most frequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), yet the mechanisms underlying it remain poorly understood. We have ...

Background/ Purpose We recently showed that in SLE, IL-4 suppressed the development of interferon-beta (IFNβ) and TLR7-stimulated T-bet + double negative 2 (DN2) B cells. Here we investigate the ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 ...

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus ...

Objective Systemic lupus erythematosus is a prevalent autoimmune disease, with 20 to 40 percent of cases exhibiting thrombocytopenia. Conventional treatments involve corticosteroids and ...